Sagimet Biosciences Inc-a (SGMT) — Institutional Holders Breakdown (Q2 2026)

SGMT ranks #4097 out of 37501 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

125 institutions disclose a position in SGMT, but none treat it as a major bet — even Great Point Partners LLC, its most concentrated holder, allocates just 3.0% of its own portfolio to it.

Federated Hermes, Inc. has added to its SGMT position for two straight quarters, increasing it by $16.1M to reach $16.1M today.

David Shaw has trimmed its SGMT position for two straight quarters, cutting it by $2.7M while still holding $171.4K.

SGMT is down 2.7% today, but institutions show net buying of $310.1M this quarter — a divergence between today's price move and the underlying institutional flow.

SGMT reported a net loss of $51.0M in its latest fiscal year.

• Not yet profitable — net loss of $51.0M in the latest fiscal year
• Net income declined year over year, from -$45.6M to -$51.0M
• Operating cash flow was negative, using $45.7M in cash
• Current ratio of 22.82x — enough short-term assets to cover short-term liabilities
• Liabilities run 1.05x equity — within a conventional range